Literature DB >> 11297218

Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994.

F Romano1, G Recchia, T Staniscia, A Bonitatibus, M Villa, A Nicolosi, G De Carli, S Mannino.   

Abstract

We performed this study with the aims of describing the trend of asthma-related mortality in Italy between 1980 and 1994, and to evaluate the relationship between sale estimates of beta2-agonists drugs and mortality from asthma. For asthma mortality we used data provided by National Institute of Statistics, for sale estimates of beta2-agonists we used data provided by IMS HEALTH. We calculated the gender specific age-standardized incidence rates of asthma-related deaths for all ages and for age classes. We found that estimates for asthma-related mortality steadily increased between 1980 and 1987 in both sexes, and thereafter decreased. In people, aged between 34 and 64 and over 64, death rates in males were significantly higher than in females while the rates in those aged less than 34, were mostly similar in both gender. The overall exposure to beta2-agonists (alone and in combination) increased from 1980 to 1990, remained stable between 1990 and 1993, and increased steeply in 1994. We conclude that asthma-related death rates have declined since the mid-1980's. This decline has been more pronounced in males and in the older ages, while the rates in younger patients of both genders have remained nearly unchanged. Our data do not substantiate the hypothesis of an increased risk of asthma-related mortality associated to the use of inhaled beta2-agonists in general nor fenoterol or salbutamol in particular.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11297218     DOI: 10.1023/a:1007644814153

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  24 in total

1.  Decrease in asthma mortality rate in Israel from 1991-1995: is it related to increased use of inhaled corticosteroids?

Authors:  M Goldman; M Rachmiel; L Gendler; Y Katz
Journal:  J Allergy Clin Immunol       Date:  2000-01       Impact factor: 10.793

2.  Fall and rise in asthma mortality in Italy, 1968-84.

Authors:  C La Vecchia; M Fasoli; E Negri; G Tognoni
Journal:  Int J Epidemiol       Date:  1989-12       Impact factor: 7.196

3.  Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols.

Authors:  W H Inman; A M Adelstein
Journal:  Lancet       Date:  1969-08-09       Impact factor: 79.321

4.  Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma.

Authors:  S Suissa; L Blais; P Ernst
Journal:  Eur Respir J       Date:  1994-09       Impact factor: 16.671

5.  Deaths from asthma in Italy (1974-1988): is there a relationship with changing pharmacological approaches?

Authors:  F Mormile; F Chiappini; G Feola; G Ciappi
Journal:  J Clin Epidemiol       Date:  1996-12       Impact factor: 6.437

6.  Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81.

Authors:  N Pearce; J Grainger; M Atkinson; J Crane; C Burgess; C Culling; H Windom; R Beasley
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

7.  Mortality from asthma: a new epidemic in New Zealand.

Authors:  R T Jackson; R Beaglehole; H H Rea; D C Sutherland
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-18

Review 8.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

Authors:  M R Sears; D R Taylor
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

9.  Prescribed drug therapy and near-fatal asthma attacks.

Authors:  C Burgess; N Pearce; R Thiruchelvam; R Wilkinson; C Linaker; K Woodman; J Crane; R Beasley
Journal:  Eur Respir J       Date:  1994-03       Impact factor: 16.671

10.  Trends in asthma-induced mortality in France from 1970-90.

Authors:  J Cooreman; C Ségala; C Henry; F Neukirch
Journal:  Tuber Lung Dis       Date:  1994-06
View more
  1 in total

1.  Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.